Amundi’s Regencell Bioscience RGC Stock Holding History

Amundi’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$219K	Buy	+8,595	New	+$243K	﹤0.01%	1848

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Amundi's RGC Position: Q1 2026 in Review

Amundi opened a new position in Regencell Bioscience (RGC) in Q1 2026: 8,595 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #1848 among its holdings.

31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

Amundi held 8,595 shares of Regencell Bioscience worth $219K as of Q1 2026.
Regencell Bioscience was a new Amundi position in Q1 2026.
Regencell Bioscience made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1848 holding.
31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.